Therapeutic Area: Pulmonary/Respiratory Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 27, 2020
Hikma will commercialize Ryaltris™ in the US following approval with the ability to produce the product utilizing its nasal manufacturing capabilities in Columbus, Ohio.